- Quote, Chart, News
- Snapshot
- Company Report
- Quotes
- Charts
- Key Developments
Recent News- Research
- SEC Filings
- Advisor FYI
- CAPS
- StockScouter
- Earnings Estimates
- Analyst Ratings
- Financial Results
- Insider Trading
- Ownership
- Message Board
- Guided Research
- Research Wizard
- Find Stocks
- Stock Screener
- Stock Power Searches
- Top-Rated Stocks
- Related Links
- Quote Watchlist
- Expert Picks
- E-mail & Alerts
- IPO Center
- Message Boards
- Capital Gains Analysis
News resources
| Wal-Mart Stores Inc (WMT) | 44 stories... |
| Google Inc (GOOG) | 42 stories... |
| Citigroup Inc (C) | 38 stories... |
| Bank of America Corp (BAC) | 36 stories... |
| Amazon.com Inc (AMZN) | 35 stories... |
| advertisement |
Crucell ADR Reptg 1 Ord Shs: All Recent News
- Vaccines on horizon for AIDS, Alzheimer's, herpes 11/18/2009
- MARIETTA, Pa. (AP) - Malaria. Tuberculosis. Alzheimer's disease. AIDS. Pandemic flu. Genital herpes. Urinary tract infections. Grass allergies. Traveler's diarrhea. You name it, the pharmaceutical industry is working on a vaccine to prevent it. Associated Press
- Crucell launches global brand to reflect and reinforce its... 11/16/2009
- Globalbiopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL) (SWISS: CRX) today announced the launch of the global Crucellbrand, a consistent identity for its worldwide activities andproducts. The rebranding is designed to promote recognition of theCrucell name and what it stands for: bringing meaningful innovationto global health, with a focus on combating infectious diseases. Theestablishment of a strong global brand will significantly supportthis mission. Market Wire
- TapImmune Signs License Agreement With Crucell N.V. 11/5/2009
- BELLEVUE, Wash., Nov. 5, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed a license agreement with Crucell N.V. GlobeNewswire
- Crucell 3Q profit falls 22 percent 11/3/2009
- NEW YORK (AP) - Dutch biotechnology company Crucell NV said Tuesday its third-quarter profit fell 22 percent as a stronger U.S. dollar and the timing of milestone payments cut into margins. Associated Press
- Calmune and Crucell Enter Exclusive Research Collaboration 11/3/2009
- Calmune Corporation, a privately heldbiotechnology company developing novel antibodies to address unmet clinicalneeds, announced today that it has established an exclusive researchcollaboration with Crucell N.V. (EURONEXT: CRXL) (NASDAQ: CRXL) (SWISS: CRX), a global biopharmaceutical company based in Leiden, the Netherlands,focusing on research development, production and marketing of vaccines,proteins and antibodies that prevent and/or treat infectious diseases.Financial details of the agreement were not disclosed. Market Wire
- Crucell Announces Third Quarter 2009 Results 11/3/2009
- ... Market Wire
- 2 Stocks Hitting Low Notes 10/28/2009
- These stocks have hit bottom. Are they ready to bounce? At Motley Fool
- Crucell to Release Q3 2009 Results on Tuesday November 3, 2009 10/27/2009
- Dutch biopharmaceuticalcompany Crucell N.V. (Euronext, Nasdaq: CRXL) (SWISS: CRX)today announced that it will release its financial results for thethird quarter 2009 on Tuesday November 3, 2009 at 07:45 CentralEuropean Time (CET). Market Wire
- Market Report -- Story Stocks (CRXL) 9/28/2009
- Crucell Crucell (CRXL 22.39 -1.31) and Johnson & Johnson (JNJ 60.91 +0.29) announced a strategic collaboration this morning in which Johnson & Johnson will buy an 18% equity... Briefing.com
- More News
- Market Report
- News by Symbol
- Today's Investing Articles
- Breaking News
- News by Topic
- News by Industry
- MSNBC News
- Data providers
- Copyright © 2009 Thomson Reuters. Click for Restrictions.
- Quotes supplied by Interactive Data Real-Time Services.